Volume 1, Issue 3

• A New Possible Class of Drugs for the Treatment of Schizophrenia
  Author(s): Robert R. Conley,
  • Abstract
  • PDF
• The Use of the Theory of Planned Behavior to Predict Medication Adherence in Schizophrenia
  Author(s): Alex Kopelowicz, Charles J. Wallace, Robert Paul Liberman,Fabian Aguirre , Roberto Zarate, Jim Mintz
  • Abstract
  • PDF
• A Brief Review of a Brain Model for Schizophrenia and Other Psychotic Disorders Which Might Suggest Novel Treatment Modalities
  Author(s): Arash Javanbakht
  • Abstract
  • PDF
• All Psychosis is Not Schizophrenia, Especially Not in Women
  Author(s): Mary V. Seeman
  • Abstract
  • PDF
• Psychosis Induced by the Interaction of Memantine and Amantadine: Lending Evidence to the Glutamatergic Theory of Schizophrenia
  Author(s): David R. Spiegel, Michael R. Leader
  • Abstract
  • PDF
• Clozapine Treatment in a Patient with a Persistently Low Neutrophil Count
  Author(s): James J. Gugger, Charles F. Caley
  • Abstract
  • PDF
• Dual Diagnosis of Substance Abuse and Schizophrenia: Improving Compliance with Pharmacotherapy
  Author(s): Samuel Keith
  • Abstract
  • PDF
• Amelioration of Negative Symptoms in Schizophrenia by Escitalopram: A Double-Blind, PlaceboControlled Clinical Trial
  Author(s): Saeed Shoja Shafti
  • Abstract
  • PDF
• Cognitive Profile During Remission: Euthymic Bipolar Disorder Patients Compared to Schizophrenia Patients
  Author(s): Yoram Braw, Yuval Bloch, Shlomo Mendelovich, Gideon Ratzoni, Hagai Harari, Shmuel Kron, Yechiel Levkovitz
  • Abstract
  • PDF